Core Strategy Directions - The focus is on five core strategic directions: innovation-driven development, industrial collaboration, open leadership, green development, and collaborative governance to establish a significant economic and technological innovation center in the region [2][3]. Innovation and Production Capacity - The strategy aims to address the issues of dispersed scientific innovation resources and inefficient results transformation by building a high-level innovation platform matrix and enhancing collaboration between Chongqing and Chengdu [2]. - Key areas of focus include artificial intelligence, low-altitude economy, and biomanufacturing, with plans to establish new research institutions and attract high-end talent [2]. Modern Industrial System - The goal is to construct a modern industrial system that emphasizes both quality and efficiency, transitioning from mere scale expansion to a balanced approach [3]. - Collaborative efforts will be made to build world-class industrial clusters in electronic information and advanced materials, with specific roles for Chengdu and Chongqing in research and high-end manufacturing [3]. Open Economy and Connectivity - The initiative aims to create a new inland open highland by enhancing the logistics network, including the Western Land-Sea New Corridor and the China-Europe Railway Express [3]. - There will be a focus on innovative institutional frameworks in cross-border service trade and digital trade, alongside efforts to attract multinational companies to establish regional headquarters [3]. Green Development - The strategy includes establishing a collaborative governance mechanism for environmental protection, focusing on pollution control in cross-border rivers and air quality [3]. - There will be an emphasis on energy-saving transformations in traditional industries and the cultivation of green industrial clusters [3]. Integrated Governance - The approach advocates for a unified strategy across the Sichuan-Chongqing region, promoting market-oriented reforms for resource allocation and enhancing public service integration [4]. - The aim is to create a one-hour commuting circle and establish a mechanism for integrated planning and project assessment to maximize collaborative development benefits [4].

Core Viewpoint - Fujian Pharmaceutical is experiencing significant operational improvement in 2025, driven primarily by its lithium battery electrolyte additive business, which has benefited from rising demand in the power battery and energy storage markets [1][5]. Group 1: Business Performance - The lithium battery electrolyte additive products, such as VC and FEC, saw a substantial price increase in Q4 2025, with battery-grade VC averaging 164,000 yuan/ton, up over 200% from the low in September [1]. - The pharmaceutical manufacturing segment has optimized steadily despite intense market competition, with a decrease in the price of key raw materials like 6-APA, leading to an improvement in gross margins [1][2]. - The company reported a net loss of 39 million to 57 million yuan for the year, marking a significant reduction in losses, and achieved profitability in Q4, indicating a positive trend in operational performance [5]. Group 2: Future Outlook - The synthetic biological microbial protein business achieved critical breakthroughs in 2025, obtaining multiple certifications that pave the way for large-scale production, although its contribution to 2025's performance is limited [3]. - For 2026, the company plans to consolidate its market position in pharmaceuticals, leverage price increases in the new energy sector, and accelerate the development of the microbial protein project to enhance capacity and market presence [3].

Core Viewpoint - The article discusses the Guangdong Provincial Government's action plan to accelerate the construction of a bio-manufacturing industry innovation highland, emphasizing the integration of bio-manufacturing across various sectors, including chemicals, energy, and cosmetics [3][4][9]. Group 1: Bio-Manufacturing in Chemicals - The plan aims to enhance the development of bio-based fine chemicals, promoting high-value products and encouraging collaboration between enterprises and research institutions for efficient synthesis routes [3]. - It supports the industrial application of bio-based bulk chemicals and materials, focusing on the development of bio-based plastics, rubber, and fibers for various industries [3]. - The initiative also seeks to advance the cosmetics and medical beauty sectors by overcoming production bottlenecks and promoting the internationalization of beauty products [3]. Group 2: Bio-Manufacturing in Energy - The action plan aligns with the national "dual carbon" strategy, promoting the diversified development of bioenergy products and increasing their production and consumption [4]. - It emphasizes the development of bio-liquid fuels, including biodiesel and bioethanol, and encourages their application in key sectors like transportation and agriculture [4]. - The plan also focuses on bio-natural gas and bio-hydrogen technologies, promoting their commercialization and integration into clean energy solutions [4]. Group 3: Overall Goals - By 2027, the plan aims to significantly enhance bio-technology innovation capabilities, establish a complete bio-manufacturing industry chain, and create a competitive bio-manufacturing industry cluster [10]. - The target includes achieving a 40% self-sufficiency rate in core strains, establishing 3-5 national bio-manufacturing innovation platforms, and generating a total output value of approximately 500 billion yuan [10]. - By 2035, the bio-manufacturing industry is expected to reach a total output value of over 1 trillion yuan, becoming a major driver of new productive forces [10].

Core Insights - The article discusses the "5th China Synthetic Biology and Biomanufacturing Conference" scheduled for March 31 to April 1, 2026, in Hangzhou, focusing on innovative synthetic biology projects and providing a platform for interaction among founders, industry experts, investors, and government representatives [3][5][6]. Event Details - The conference will take place in Hangzhou with an expected attendance of 1,000 participants [6]. - The event is organized by synbio深波 and hosted by 享融智云 [6]. - Media support will come from various platforms including synbio新农食 and synbio新美护 [7]. Conference Agenda - The agenda includes multiple sessions over two days, covering topics such as biomanufacturing industry ecology, functional foods, and applications of synthetic biology [7]. - Specific sessions include "New Growth · New Breakthroughs: Biomanufacturing Industry Ecology Conference" and "Future Foods and All-Age Nutrition Special" [7]. Roadshow Participation - A roadshow segment is included to showcase innovative synthetic biology projects, with a limited time of 8-10 minutes per project for presentations [8]. - Interested participants must submit a brief project introduction related to synthetic biology and biomanufacturing, with limited slots available on a first-come, first-served basis [8][11]. Previous Roadshow Highlights - Past roadshow projects have included topics such as efficient production of terpenoids, enzyme development, and applications of synthetic biology in skincare and agriculture [8][9]. - Notable projects from previous years highlight advancements in biomanufacturing and the integration of AI with synthetic biology [8][9].

（来源：千龙网） 26日的发布会上，北京市科委、中关村管委会党组成员、副主任翟天瑞介绍，"十五五"时期，北京将通 过多维举措全面激活科技创新动能，推动区域创新发展提质增效。推动在京全国重点实验室集群式发 展。 为巩固科技创新策源引领优势，北京将进一步完善部市合作机制，支持国家实验室牵头承担国家科技重 大专项，跨区域整合创新资源。同时，推动在京全国重点实验室集群式发展，助力清华大学南口全国重 点实验室基地、北京大学昌平产教研融合创新中心建设，强化怀柔重大科技基础设施集群的后续建设与 开放运行。此外，还将支持高水平研究型大学开展使命导向的科技创新，承担国家及区域重大科技攻关 任务，支持中国科学院等国家科研机构在京布局，持续实施攻坚专项和先导专项。 人才是科技创新的核心支撑。翟天瑞表示，北京将大力引进战略科学家、科技领军人才及青年人才，通 过多举措强化人才培育与保障。深化"新工科"建设，鼓励高校超常规布局前沿学科、交叉学科、新兴学 科，引导市属高校新增急需紧缺学科专业和学位授予点；推动"双一流"高校有序扩大招生规模，深化产 教融合协同育人，推进工程硕博士培养改革专项试点，吸纳更多高校与科技型企业参与。同时，布局新 ...

1月26日， 天津市第十八届人民代表大会第四次会议在天津礼堂开幕。 记者 佟郁 摄 同日提交大会审议的《天津市国民经济和社会发展第十五个五年规划纲要(草案)》亦提出，将依托先进 医用材料与医疗器械全国重点实验室、脑机交互与人机共融海河实验室、天津市脑机接口创新中心等平 台，联合南开大学、天津大学等单位，积极争创脑机接口领域国家技术创新中心。 根据上述规划草案，天津将加快脑机接口、类脑芯片、类脑计算机关键算法、人机交互底层核心器件等 研发与成果转化，推动脑机交互技术在医疗科研、运动与感知辅助、游戏娱乐、学习教育、智能家居等 领域的应用，加速推动一批重大科技成果落地转化。(完) 中新网天津1月26日电 (记者 周亚强)天津市第十八届人民代表大会第四次会议26日开幕，市长张工作政 府工作报告(下称"报告")。报告提出，天津将争建国家脑机接口技术创新中心，在关键技术突破上作 出"天津创新贡献"。 报告称，天津将积极共建北京(京津冀)国际科技创新中心，聚焦本地优势与需求，畅通与驻津央院央 所、高校研发平台等"握手"通道，推进科研设备共享、设施共同、团队梯次共建，支持"六链五群"重点 企业与战略科技力量加强产学研合作。 ...

Group 1 - The core issue facing Huaxi Biological is a dual challenge of capital and performance, with frequent shareholder sell-offs, declining performance, and significant market value reduction [1][6] - The second-largest shareholder, Guoshou Chengda, has reduced its stake from 7.15% to 4.01% since October 2024, cashing out approximately 769 million yuan through two large-scale sell-offs, signaling a strong capital exit and reflecting cautious sentiment from institutional investors [2][7][8] - The company's market value has shrunk to about 22.2 billion yuan, far from its peak of over 100 billion yuan, indicating a loss of market confidence [8] Group 2 - Huaxi Biological's revenue and net profit have entered a downward trend, with a reported revenue decline of 11.61% and a net profit drop of 70.59% in 2024, followed by an 18.36% revenue decline and a 30.29% net profit decrease in the first three quarters of 2025 [3][9] - The company has initiated a series of business contraction actions, including the closure of several sub-brands and focusing resources on core brands like "Runbaiyan" and "Kuaidi," which highlights the challenges faced in previous diversification efforts [3][9] - Despite some recovery in net profit in the second and third quarters of 2025 due to cost-cutting measures, the overall revenue scale continues to shrink, indicating ongoing struggles [3][9] Group 3 - The return of founder Zhao Yan has led to initial success in cost control, achieving a temporary halt in losses, but the company has yet to demonstrate sustainable revenue generation capabilities [4][10] - Huaxi Biological is advancing research projects in synthetic biology, including injectable recombinant collagen and VAHA, which are in trial production stages, potentially opening a new growth avenue if these products can achieve market competitiveness [4][10] - The transition from research and development to market success involves overcoming multiple technical, market, and cost barriers, which remains a significant challenge for the company [4][10] Conclusion - The difficulties faced by Huaxi Biological reflect typical challenges for high-growth companies entering an adjustment phase, including a retreat of capital enthusiasm, a shift in growth models, and a gap between old and new business lines [5][11] - While the company has taken critical steps towards focusing its operations, moving from cost-cutting to revenue generation and achieving breakthroughs in core brand competitiveness and commercialization of R&D results remains essential for future recovery [5][11]

Core Viewpoint - AiBio (Hangzhou) Biotechnology Co., Ltd. has completed a Pre-A round financing of several tens of millions, positioning itself as a leading provider of bio-manufacturing technology services and products, integrating biological engineering and artificial intelligence [2]. Group 1: Core Technology Platform - The AIxBio intelligent fermentation platform integrates cutting-edge technologies such as enzyme engineering, gene editing, and metabolic network modification, allowing for the simulation of complex fermentation environments and prediction of bioreactor fluid behavior, addressing the common "scale-up effect" issue in synthetic biology [3]. Group 2: Product Pipeline - The product pipeline focuses on the beauty and health sector, particularly the development of high-activity peptide raw materials: - The "001 series" peptide products are developed in collaboration with Huisi Le, utilizing AI technology for sequence optimization and expression system construction to achieve efficient and low-cost production [4]. - The company is developing a series of bioactive peptide molecules for high-end skincare products and functional foods based on its gene editing and metabolic network modification platform [4]. - AiBio also offers customized bio-manufacturing services, providing comprehensive technical solutions from strain modification to process scaling for partners [4].

Core Viewpoint - The stock of Yaoshi Technology has shown fluctuations in price and trading volume, with a notable increase in revenue but a decrease in net profit for the year 2025 [1][2]. Group 1: Stock Performance - On January 21, Yaoshi Technology's stock rose by 2.08%, reaching 43.67 CNY per share, with a trading volume of 1.84 billion CNY and a turnover rate of 2.11%, resulting in a total market capitalization of 10.21 billion CNY [1]. - Year-to-date, the stock price has increased by 13.25%, but it has decreased by 8.51% over the last five trading days [1]. - The stock has shown a 13.31% increase over the last 20 days and a 7.09% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Yaoshi Technology reported a revenue of 1.419 billion CNY, reflecting a year-on-year growth of 25.81% [2]. - The net profit attributable to shareholders for the same period was 113 million CNY, which represents a year-on-year decrease of 13.96% [2]. Group 3: Shareholder Information - As of December 31, the number of shareholders for Yaoshi Technology was 42,500, a decrease of 1.09% from the previous period [2]. - The average number of tradable shares per shareholder increased by 1.10% to 4,770 shares [2]. - The company has distributed a total of 231 million CNY in dividends since its A-share listing, with 137 million CNY distributed over the last three years [3].

Core Viewpoint - Xinhua Medical has experienced fluctuations in stock price and financial performance, with a notable decrease in revenue and net profit year-on-year, indicating potential challenges in the medical device sector [1][2]. Group 1: Stock Performance - On January 21, Xinhua Medical's stock rose by 2.05%, reaching 16.42 CNY per share, with a trading volume of 120 million CNY and a turnover rate of 1.22%, resulting in a total market capitalization of 9.961 billion CNY [1]. - Year-to-date, Xinhua Medical's stock price has increased by 14.03%, but it has seen a decline of 2.26% over the last five trading days, a rise of 12.16% over the last 20 days, and a modest increase of 1.67% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Xinhua Medical reported a revenue of 6.978 billion CNY, reflecting a year-on-year decrease of 6.00%, while the net profit attributable to shareholders was 434 million CNY, down 29.61% compared to the previous year [2]. - Since its A-share listing, Xinhua Medical has distributed a total of 9.63 billion CNY in dividends, with 607 million CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Xinhua Medical was 38,700, a decrease of 1.44% from the previous period, with an average of 15,610 circulating shares per shareholder, which is an increase of 1.46% [2]. - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF holds 13.7328 million shares, a decrease of 2.3604 million shares from the previous period, while Hong Kong Central Clearing Limited increased its holdings by 768,900 shares to 8.6891 million shares [3].